A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 76, Issue 3, 2017, Pages 566-570

  Yoo, Dae Hyun ^a   Suh, Chang Hee ^b   Shim, Seung Cheol ^c   Jeka, Slawomir ^d   Cons Molina, Francisco Fidencio ^e   Hrycaj, Pawel ^f   Wiland, Piotr ^g   Lee, Eun Young ^h   Medina Rodriguez, Francisco G ⁱ   Shesternya, Pavel ^j   Radominski, Sebastiao ^k   Stanislav, Marina ^l   Kovalenko, Volodymyr ^m   Sheen, Dong Hyuk ⁿ   Myasoutova, Leysan ^o   Lim, Mie Jin ^p   Choe, Jung Yoon ^q   Lee, Sang Joon ^r   Lee, Sung Young ^r   Kwon, Taek Sang ^r   Park, Won ^p   more..

^a Hanyang University Hospital for Rheumatic Diseases   (South Korea)

^b Ajou University Medical CentSuwon   (South Korea)

^c Chungnam National University College of Medicine   (South Korea)

^d NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^e Centro de Investigacion en Artritis y Osteoporosis   (Mexico)

^f POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

^h Seoul National University College of Medicine   (South Korea)

ⁱ LA SALLE UNIVERSITY   (United States)

^j KRASNOYARSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^k FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^l V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^m Institute for Agricultural Engineering and Electrification   (Ukraine)

ⁿ Eulji University   (South Korea)

^o Scientific Medical Research Complex Vashe Zdorovie   (Russian Federation)

^p Inha University   (South Korea)

^q Catholic University of Daegu   (South Korea)

^r Celltrion Inc   (South Korea)

more..

Author keywords

B cells; DMARDs (biologic); Pharmacokinetics; Rheumatoid Arthritis; Treatment

Indexed keywords

BIOSIMILAR AGENT; CD19 ANTIGEN; CT P10; DRUG ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; ANTIBODY; ANTIRHEUMATIC AGENT; METHOTREXATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; B LYMPHOCYTE; BIOEQUIVALENCE; CONTROLLED STUDY; DAS28; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ELIMINATION HALF-LIFE; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; INFECTION; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; IMMUNOLOGY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THERAPEUTIC EQUIVALENCE;

ADULT; ANTIBODIES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RITUXIMAB; SEVERITY OF ILLNESS INDEX; THERAPEUTIC EQUIVALENCY;

EID: 84987818368     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209540     Document Type: Article

References (11)

1. Bugatti S, Vitolo B, Caporali R, et al. B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers. Biomed Res Int 2014;2014:681678.
2. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
3. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
4. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005 Rev1. December 2014. http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2015/01/WC500180219.pdf (accessed 11 Feb, 2016).
5. U.S. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. April 2015. http://www. fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/ UCM291128.pdf (accessed 11 Feb 2016).
6. Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005;45:792-801.
7. Breedveld F, Agarwal S, Yin M, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007;47:1119-28.
8. European Medicines Agency. MabThera (rituximab) Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR - -Product-Information/human/000165/WC500025821.pdf (accessed 11 Feb 2016).
9. Kim JS, Kim SH, Kwon B, et al. Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13). Expert Rev Clin Immunol 2015;11(Suppl. 1):S33-41.
10. Chen K, Page JG, Schwartz AM, et al. False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay. J Immunol Methods 2013;394:22-31.
11. van Vollenhoven RF, Emery P, Bingham CO III, et al Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010;37:558-67.